Home › Research › Biomarkers
Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study
Jiang X, Hoang TD, Shaw LM, Jacobs DR, Nasrallah IM, Bryan RN, Yaffe K.. Lancet (London, England), 2026-05-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease neuropathology positivity was present in 86 (6%) participants based on p-tau217/Aβ42, 196 (15%) based on Aβ42/40, and 48 (4%) based on p-tau217, and was associated with worse performance on processing speed (standardised cognitive difference comparing Alzheimer's disease neuropathology positive to negative for Aβ42/40, p-tau217, and p-tau217/Aβ42 -0·54 to -0·25; p values 0·0001 to 0·0048) and executive function (-0·42 to -0·19; p values 0·0070 to 0·049). Alzheimer's disease neuropathology positivity was also associated with increased odds of accelerated decline on verbal memory (Aβ42/40: odds ratio 4·31, 95% CI 1·71-10·9, p-tau217/Aβ42: 2·44, 1·16-5·13) and processing speed (p-tau217: 3·98, 1·71-9·3; p-tau217/Aβ42: 3·35, 1·77-6·35) compared with Alzheimer's disease neuropathology negativity. Interpretation Alzheimer's disease neuropathology is relatively uncommon in midlife but associated with worse cognitive performance and accelerated decline and might have stronger association among some groups.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jiang, X., Hoang, T. D., Shaw, L. M., Jacobs, D. R., Nasrallah, I. M., Bryan, R. N., et al. (2026). Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00515-5
Vancouver
Jiang X, Hoang TD, Shaw LM, Jacobs DR, Nasrallah IM, Bryan RN, et al. Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study. Lancet (London, England). 2026. doi:10.1016/s0140-6736(26)00515-5. PMID: 42208562.
BibTeX
@article{jiang2026-42208562,
author = {Jiang, X. and Hoang, T. D. and Shaw, L. M. and Jacobs, D. R. and Nasrallah, I. M. and Bryan, R. N. and Yaffe, K.},
title = {{Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study}},
journal = {Lancet (London, England)},
year = {2026},
doi = {10.1016/s0140-6736(26)00515-5},
pmid = {42208562},
url = {https://doi.org/10.1016/s0140-6736(26)00515-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Alzheimer's disease neuropathology positivity was present in 86 (6%) participants based on p-tau217/Aβ42, 196 (15%) based on Aβ42/40, and 48 (4%) based on p-tau217, and was associated with worse performance on processing speed (standardised cognitive difference comparing Alzheimer's disease neuropathology positive to negative for Aβ42/40, p-tau217, and p-tau217/Aβ42 -0·54 to -0·25; p values 0·0001 to 0·0048) and executive function (-0·42 to -0·19; p values 0·0070 to 0·049).
- Alzheimer's disease neuropathology positivity was also associated with increased odds of accelerated decline on verbal memory (Aβ42/40: odds ratio 4·31, 95% CI 1·71-10·9, p-tau217/Aβ42: 2·44, 1·16-5·13) and processing speed (p-tau217: 3·98, 1·71-9·3; p-tau217/Aβ42: 3·35, 1·77-6·35) compared with Alzheimer's disease neuropathology negativity.
- Interpretation Alzheimer's disease neuropathology is relatively uncommon in midlife but associated with worse cognitive performance and accelerated decline and might have stronger association among some groups.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants1,500
- Evidence strengthModerate
How this study scored 74/100
Published in a top-tier journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 43 of the 58 points we could judge it on, which is 74 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Lancet (London, England)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,500 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42208562) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 43 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 43 of the 58 points we could judge it on is 74 out of 100. |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “midlife”
3 studies in the library carry the topic tag “midlife”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.